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Abstract 26 
Within this paper we present work that has the ability to de-risk the translation of liposomes from 27 
bench to the clinic. We have used microfluidics for the rapid and scale-independent manufacture of 28 
liposomes and have incorporated in-line purification and at-line monitoring of particle size. Using this 29 
process, we have manufactured a range of neutral and anionic liposomes incorporating protein. 30 
Factors investigated include the microfluidics operating parameters (flow rate ratio (FRR) and total 31 
flow rate (TFR)) and the liposome formulation. From these studies, we demonstrate that FRR is a key 32 
factor influencing liposome size, protein loading and release profiles. The liposome formulations 33 
produced by microfluidics offer high protein loading (20-35 %) compared to production by sonication 34 
or extrusion (< 5%). This high loading achieved by microfluidics results from the manufacturing process 35 
and is independent of lipid selection and concentration across the range tested. Using in-line 36 
purification and at-line size monitoring, we outline the normal operating range for effective 37 
production of size controlled (60 to 100 nm), homogenous (PDI <0.2) high load liposomes. This easy 38 
microfluidic process provides a translational manufacturing pathway for liposomes in a wide-range of 39 
applications.  40 
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1. Introduction 41 
Protein-based therapies are a key tool in healthcare with approximately 240 FDA approved protein 42 
and peptides available (Fosgerau and Hoffmann, 2015; Lu et al., 2014; Usmani et al., 2017). These 43 
proteins and peptides can be used for the treatment and amelioration of a range of diseases as well 44 
as used for diagnostic purposes and vaccines (Carter, 2011). However, there are still a number of 45 
associated challenges with the delivery of proteins including their sensitivity to both chemical and 46 
physical degradation which can result in low bioavailability and short half-life after in vivo 47 
administration (Lee and Yuk, 2007). To address this, a wide range of drug delivery systems have been 48 
investigated including liposomes. Liposomes can offer targeting, protection to their payload, high 49 
biocompatibility and low toxicity (Torchilin and Lukyanov, 2003) and there are a notable number of 50 
liposomal formulations on the market or undergoing trials, including a range of anticancer agents, 51 
antifungal systems and vaccines such as Inflexal V – a virosome-based vaccine formulation for 52 
influenza (Bulbake et al., 2017). 53 
However, the manufacture and production of liposomes is challenging, particularly when considering 54 
the entrapment of proteins. Manufacturing conditions including temperature, high pressure, non-55 
aqueous solvents, metal ions, detergents, incompatible pH and/or ionic strength, and shearing can all 56 
impact on the chemical and physical stability of proteins. Furthermore, many of the methods adopted 57 
give poor encapsulation efficiency, as summarised in Table 1. Although methods such as reverse phase 58 
evaporation have been developed to combat some of these issues, this process offers limited size 59 
control and produces formulations that are very heterogeneous (Szoka and Papahadjopoulos, 1978).  60 
In addition to this, the liposome formulation can also influence protein encapsulation with factors 61 
such as the lipid(s) used, the amount of cholesterol and protein concentration all shown to effect the 62 
amount of protein encapsulation (Xu et al., 2012). 63 
Microfluidics is an alternative technology that can be used to produce liposomes. It uses a lab-on-a-64 
chip approach and can be defined as the manipulation of small volumes in a controlled microchannel 65 
environment, which encourages mixing (Whitesides, 2006). Microfluidics, unlike the thin film lipid 66 
hydration method, produces liposomes using a ‘bottom-up’ approach (Akbarzadeh et al., 2013). In 67 
contrast to ‘top-down’ methods which rely on size reduction of larger multilamellar vesicles, 68 
microfluidics results in the formation of small liposomes from individual lipid monomers and thus no 69 
additional size reduction method is needed. Microfluidics offers both ease of scale-up and use for high 70 
throughput screening as it can also run with small quantities, whilst maintaining high resolution and 71 
sensitivity. This, along with the fact it can decrease production cost and time has led to microfluidics 72 
becoming increasingly popular in the pharmaceutical industry.  73 
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In microfluidics cartridges, fluid flows through micro-channels that converge; the organic phase (lipids 74 
dissolved in alcohol) flows through one channel whilst the aqueous phase (buffer) flows through the 75 
other. From the point the two fluid streams converge formation of liposomes begins to occur at the 76 
liquid interface. The mixing of the organic phase with the aqueous phase causes a decrease in the 77 
concentration of alcohol, due to diffusion (Capretto et al., 2013). As such, the low concentration of 78 
alcohol causes an increase in polarity and the lipids to precipitate, resulting in the self-assembly of 79 
vesicles with a lipid bilayer and an aqueous core (Jahn et al., 2010; Zook and Vreeland, 2010). Assembly 80 
can be controlled by varying the speed (known as the Total Flow Rate (TFR)) and mixing ratio (referred 81 
to as the Flow Rate Ratio) of the fluid flows through the channels (Jahn et al., 2007). Recently, several 82 
studies have shown the potential of microfluidics to produce liposomes in a range of sizes, as well as 83 
encapsulate different materials including small interfering RNA (Belliveau et al., 2012; Chen et al., 84 
2012), low solubility drugs (Kastner et al., 2015), and combinations of aqueous and bilayer drug loaded 85 
liposomes (Joshi et al., 2016). Furthermore, Dimov et al (Dimov et al., 2017), demonstrated a lab-on-86 
bench scale set-up for the manufacture of liposomes in a scale independent manner using novel 87 
engineered equipment. Nonetheless, whilst research has shown the ability to encapsulate a range of 88 
biologics, the ability to scale up this process has not been systematically explored. Therefore, within 89 
this paper we investigate and demonstrate the use of microfluidics to encapsulate proteins in a scale-90 
independent manner and we incorporate in-line purification and at-line particle size monitoring for 91 
in-process control and as a product validation tool.  92 
2. Materials and Methods. 93 
2.1 Materials 94 
The lipids  egg phosphatidylcholine (PC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-95 
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 96 
and L-α-phosphatidylserine (Brain PS, Porcine) were all purchased from Avanti Polar Lipids Inc., 97 
Alabaster, AL, US. Cholesterol (cholesterol), Insulin, Ovalbumin (OVA), bovine serum albumin (BSA), 98 
Sucrose, trifluoroacetic acid and D9777-100ft dialysis tubing cellulose were purchased from Sigma 99 
Aldrich Company Ltd., Poole, UK. For ovalbumin purification by Tangential flow filtration (TFF), a 100 
modified polyethersulfone (mPES) 750 kD MWCO hollow fibre column was used (Spectrum Inc., Breda, 101 
The Netherlands). For release studies, Biotech CE Tubing MWCO 300 kD was used (Spectrum Inc., 102 
Breda, The Netherlands). A Jupiter column (C18 (300 Å), 5 µm, dimensions 4.60 X 150 mm) and a Luna 103 
column (C18(2), 5 µm, dimensions 4.60 X 150 mm, pore size 100 Å) was used in HPLC and purchased 104 
from Phenomenex., Macclesfield, UK. The Pierce™ BCA Protein Assay kit, Dil Stain (1,1’-Dioctadecyl-105 
3,3,3’,3’- Tetramethylindocarbocyanine Perchlorate (‘Dil’; DilC18 (3)), HPLC grade methanol and 2-106 
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propanol were purchased from Fisher Scientific, Loughborough, England, UK. All water and solvents 107 
used were HPLC grade. 108 
2.2. Liposome production  109 
2.2.1 Liposomes prepared by extrusion and sonication 110 
Lipids were dissolved at required concentrations in a chloroform:methanol mixture (v/v 9:1) and 111 
placed under vacuum via rotatory evaporation for 6 minutes at 200 rpm in a heated (37oC) water bath 112 
to remove solvent. Hydration of the lipid film and protein encapsulation was achieved by the addition 113 
of phosphate buffered saline (PBS) (pH 7.3 ± 0.2) containing ovalbumin (0.25 mg/mL) at temperatures 114 
above the appropriate lipid transition temperature. Hand held extrusion was conducted on 115 
multilamellar vesicles (MLV) using a Mini Extruder from Avanti Polar Lipids Inc., Alabaster, AL, US. 116 
Liposomes (1 mg/mL) were extruded through incrementally decreasing pore sized membranes (0.5 – 117 
0.2 µm), with each sample being cycled through ten times. During extrusion, liposomes were held 118 
above their appropriate transition temperature. Size reduction of multilamellar vesicles was also 119 
achieved via sonication using a 9.5 mm titanium probe sonicator (Soniprep 150, MSE labs, UK) for 4 120 
minutes at 10 Hz. Again during this process, liposomes were held above their appropriate transition 121 
temperature.  122 
2.2.2. Liposomes prepared by microfluidics 123 
The preparation of liposomes by microfluidics was conducted on the Nanoasemblr® Benchtop system 124 
from Precision Nanosystems. Selected lipids were dissolved in methanol at specific concentrations 125 
(ranging primarily between 0.3 – 10 mg/mL total lipid) and injected through one of the two inlets on 126 
the microfluidics herringbone micromixer chip, whilst the aqueous phase (PBS; pH 7.3 ± 0.2) is injected 127 
into the second inlet. A number of production parameters can be controlled using the Nanoassemblr® 128 
software including the flow rate ratio (the ratio between the aqueous phase and the lipid phase) and 129 
the total flow rate (the speed at which the two inlets are injected through the chip). Flow rate ratios 130 
of 1:1, 3:1 and 5:1 were selected for testing as well as total flow rate speeds between 5 - 20 mL/min. 131 
For the production of protein loaded liposomes, ovalbumin was added to the aqueous phase at 132 
specific concentrations and the same principles for the production of empty liposomes was followed.  133 
Larger scale production of OVA loaded liposomes was prepared using the Nanoassemblr® Blaze™ (10 134 
mL to 1L) utilising the same production parameters as previously optimised on the Benchtop system 135 
(3:1 FRR, 15 mL/min), without the addition of a dilution factor. 136 
 137 
 138 
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2.3. Quantification of lipid and liposome recovery 139 
HPLC- ELSD (high performance liquid chromatography- evaporative light scattering detector) was used 140 
to quantify the lipid recovery within liposomes. A Luna column (C18(2), 5 µm, dimensions 4.60 X 150 141 
mm, pore size 100 Å) was used to detect the lipids, at a flow rate of 2 mL/min. A twenty minute elution 142 
gradient, composed of solvent A (0.1% TFA in water) and solvent B (100% methanol) was used. During 143 
the first six minutes the gradient was 15:85 (A:B), at 6.1 minutes 0:100 (A:B) and then back to the 144 
initial gradient of 15:85 (A:B) from 15.1 to 20 minutes. The lipid recovery was calculated as a 145 
percentage in comparison to the initial concentration of the stock solution. Liposome recovery was 146 
calculated by incorporating the hydrophobic dye Dil Stain (1,1’-Dioctadecyl-3,3,3’,3’- 147 
Tetramethylindocarbocyanine Perchlorate (‘Dil’; DilC18 (3)) (DilC) at 0.2 mol% into the bilayer of the 148 
liposomes. Post production and during purification, aliquots of permeate was collected during the TFF 149 
process.  150 
2.4 Liposome purification via tangential flow filtration  151 
Liposome samples were purified using Krosflo Research Iii tangential flow filtration system fitted with 152 
an mPES (modified polyethersulfone) column with a pore size of 750 kD. For removal of solvent and 153 
unentrapped protein, liposomal samples were circulated through the column and purified through 154 
difiltration, with fresh PBS being added at the same rate as the permeate leaving the column. 155 
2.5. Liposome characterisation 156 
Dynamic light scattering (DLS) was used to analyse the intensity mean diameter (z-average) and 157 
polydispersity index (PDI) of the liposomal formulations using a Malvern Zetasizer Nano-ZS (Malvern 158 
Instruments, Worcs., UK). All measurements were undertaken in triplicate. All readings were between 159 
6-9 attenuation and samples were diluted 1/10 with appropriate buffer.  To continuously monitor 160 
particle size in an at-line process, the Zetasizer AT (Malvern Panlaytical Ltd, Malvern, UK) was used. 161 
The Zetasizer AT measured liposome size and PDI at a 1:10 dilution (liposomes to buffer). A buffer flow 162 
rate of 5 mL/min and liposome formulation flow rate of 0.5 mL/min were used. A total of 1 mL was 163 
required for each size measurement.   164 
2.6. Liposome morphology  165 
Images were taken on a Jeol 2011 with a 200kv beam using minimal dose protocol, scanned at low 166 
magnification and jumped to high magnification without exposing the sample to the beam first. The 167 
camera used was a Gatan ultrascan (2k by 2k pixels). Grids were lacey carbon, 200 mesh and were 168 
prepared by adding 8 microlitres of sample to a glow discharged grid, blotting from both sides for 169 
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approximately 5 seconds then plunging into nitrogen cooled ethane propane mix (70% ethane). 170 
CryoTEM pictures were taken at Warwick University, UK by Dr Saskia Bakker, Advanced Bioimaging 171 
Platform, and University of Warwick. Evaluation was performed at 15000x magnification. 172 
2.7. Encapsulated protein quantification 173 
Solubilisation of the liposomes to release entrapped protein was achieved following a previously 174 
published protocol (Fatouros and Antimisiaris, 2002) and modified for protein formulations. Briefly, 175 
liposomal samples were added at a 50/50 v/v ratio with solubilisation mixture (PBS / 2-Propanol 50/50 176 
v/v) and vortexed. Protein quantification was then determined using either UV-HPLC or BCA protein 177 
assay.  For UV-HPLC, an Agilent 1100 Series HPLC (California, USA) was used to quantify the amount 178 
of OVA entrapped inside liposomes. All samples were run at 280 nm, using a C18 column (i.d. 150 X 179 
4.6 mm) from Phenomenex (Macclesfield, UK). A 1 mL/min flow rate was used with a twenty minute 180 
elution gradient, composed of solvent A (0.1% TFA in water) and solvent B (100% methanol). During 181 
the first ten minutes the gradient was 100: 0 (A: B), at 10.1 minutes 0: 100 (A: B) and then back to the 182 
initial gradient of 100: 0 (A: B) from 15.1 to 20 minutes. The injection volume for the sample is 20 µL. 183 
For protein release studies, HPLC was used in conjunction with a SEDEX 90LT evaporative light 184 
scattering detector (ELSD) (Sedex sedere, Alfortville, France) to quantify the amount of OVA. A Jupiter 185 
A100 column was used to detect the OVA protein. The flow rate used was 1 mL/ min, with a gain of 8 186 
and an OVA peak appearing at 11.8 minutes. A standard calibration curve for OVA was established 187 
using various concentrations; the amount of encapsulated protein in liposomes produced by 188 
microfluidics and sonication was calculated using the peak area of the sample in relation to the 189 
standards. Protein quantification using BCA/ Micro BCA protein assay was carried out as per 190 
manufacturer’s instructions. Briefly, samples were incubated with appropriate volume of working 191 
reagent and incubated at 37°C and the absorbance measured at 562 nm. Calibration curves were 192 
subjected to the inclusion of empty liposomes and solubilisation mixture and appropriate blanks were 193 
measured for subtraction of absorbance values.  194 
2.8 Circular dichroism 195 
The OVA protein integrity was tested after microfluidics and TFF. Untreated OVA (0.3 mg/ mL) in PBS 196 
was used as a control to test OVA integrity inside DSPC:Chol liposomes. The liposomes were made 197 
using 8 mg/mL initial lipid and 8 mg/ mL initial OVA at a 3:1 FRR and 15 mL/min TFR. The Chiroscan™- 198 
plus was used to analyse OVA using 20 µL of the respective samples. The sample was placed in 199 
between two microscope slides and placed into a Suprasil® quartz absorption cuvette (Hellma, 200 
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Germany: path length of 1 mm). The measurement temperature was 25 °C and spectra recorded from 201 
180-260 nm range. 202 
2.9 Protein release studies 203 
Ovalbumin loaded liposomes (PC:Chol, DMPC:Chol, DPPC:Chol and DSPC:Chol) were produced using 204 
microfluidics using a 3:1 FRR and 15 mL/min TFR (4 mg/mL initial lipid and 0.25 mg/mL Ovalbumin). 205 
The DMPC:Chol formulation was selected, and made at both a 3:1 and 5:1 FRR (the TFR used was 15 206 
mL/min). The unentrapped OVA and solvent was removed by TFF (12 mL wash cycle needed per mL 207 
of formulation). Purified formulations are used to investigate the rate of OVA release; 1 mL of the 208 
formulation was placed in a 300 kD dialysis bag in the presence of 25 mL of phosphate buffered saline 209 
(pH 7.3 ± 0.2). The samples were left for 0.5, 1, 3, 6, 18, 24, 48, 72, 96 and 120 hours at 37°C with 210 
agitation, after the allocated time the liposome formulation was collected and analysed by HPLC. 211 
2.10 Headspace Gas Chromatography 212 
Headspace gas chromatography (Agilent 7697A, Agilent Technologies, USA) was used to measure 213 
residual solvent content for liposomes produced by microfluidics and purified by tangential flow 214 
filtration. Solvent was measured using in an isothermal process using an Agilent 122-1334 column 215 
(30m x 250µm x 1.4 µm). The sample was held at 60°C for a minute before the temperature was 216 
ramped up to 80°C for 6 minutes.  217 
2.11 Statistical analysis 218 
Results are represented as mean ± SD with n = 3 independent batches. ANOVA tests were used to 219 
assess statistical significance, with a Tukey’s post adhoc test (p value of less than 0.05). Where 220 
appropriate the similarity or differences between drug release profiles from various formulations was 221 
assessed by the f2 similarity test. 222 
3. Results and Discussion 223 
3.1 Rapid and scalable manufacture of liposomes prepared by microfluidics: identifying the normal 224 
operating range.  225 
We have previously reported on the use of microfluidics to manufacture liposomes entrapping DNA 226 
(Kastner et al., 2015), low soluble drugs (Dimov et al., 2017; Kastner et al., 2015) and combinations of 227 
high and low soluble drugs (Joshi et al., 2016). To investigate this manufacturing method for the 228 
production of liposomes entrapping proteins, we first set out to identify our working parameters in 229 
terms of the effect of lipid selection, initial lipid concentration, flow rate ratio, total flow rate and 230 
manufacturing temperature (given the potential sensitivity of drugs and proteins to temperature 231 
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instabilities). To achieve this, four liposome formulations were prepared using phospholipids with 232 
increasing hydrocarbon tail length (and lipid phase transition temperature) i.e. PC:Chol, DMPC:Chol, 233 
DPPC:Chol and DSPC:Chol. Liposomes were produced at a 3:1 FRR and a 15 mL/min TFR and the effect 234 
of the hydrocarbon tail length of the PC on the resulting liposomes size and PDI was investigated post 235 
solvent removal (Figure 1).  236 
Results in Figure 1A show that as we increase our phospholipid alkyl chain length (from PC up to DSPC) 237 
we see a trend of decreasing vesicle size. This trend of decreasing liposome size with increasing alkyl 238 
chain length is evident across all concentrations tested (from 0.3 mg/mL to 10 mg/mL; Figure 1A). For 239 
example, at the lowest lipid concentration tested (0.3 mg/mL initial concentration) liposomes reduced 240 
significantly (p<0.05) from approximately 100 nm down to 60 nm in size. At the highest lipid 241 
concentration (10 mg/mL), the reduction was less notable but still significant (p<0.05) with liposomes 242 
reducing from 70 to 45 nm (Figure 1A). Figure 1A also shows that with increasing initial lipid 243 
concentrations, liposome size also decreases irrespective of the lipid selected (Figure 1A); as we 244 
increase from 0.3 to 10 mg/mL initial lipid concentration, PC liposomes reduce from approximately 245 
100 nm to 70 nm, DMPC liposomes reduce from 75 to 60 nm, DPPC liposomes reduce from 70 to 45 246 
nm, and DSPC liposomes reduce from 55 to 45 nm; Figure 1A). This link between lipid concentration 247 
and liposome size is in line with previously reported studies (Joshi et al., 2016) where we investigated 248 
PC:Chol liposomes. In Figure 1A we now demonstrate this effect applies to a range of liposome 249 
formulations and the lipid recovery after microfluidic production was also high (>94%) for all 4 250 
formulations tested (Table 2). 251 
To consider if the reduction in vesicle size was related to lipid alkyl chain length or lipid transition 252 
temperature, we also compared liposomes prepared using two lipids with the same alkyl chain length 253 
(18 carbons) but different transition temperatures: DSPC (Tm of 55oC) and DOPC (Tm of -17oC). Table 254 
3 shows that liposomes formed using DOPC were approximately 40 nm larger in size than DSPC. This 255 
suggests that whilst adopting longer alkyl chain length PCs within the liposome formulation can reduce 256 
vesicle size, the degree of saturation and the ability of these PC to pack within a bilayer must also be 257 
considered. Irrespective of the lipid concentration, the lipid transition temperature and lipid alkyl 258 
chain length, all liposome formulations were produced with low PDI values (<0.2; Figure 1B) 259 
demonstrating the highly homogenous nature of the liposomal products produced via microfluidics. 260 
Thus, across all formulations, liposomes could easily be formulated to sizes below 100 nm with low 261 
PDI values.  262 
Generally in the production of liposomes using lipid-hydration methods, liposomes must be formed 263 
above their transition temperature (Szoka Jr and Papahadjopoulos, 1980) with for example DSPC 264 
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liposomes commonly being prepared above 55oC. This can present issues for thermo-liable drugs and 265 
proteins. However, the addition of 50% mol/mol cholesterol has been shown by differential scanning 266 
calorimetry to abolish the gel-to-liquid phase transition temperature of DSPC liposomes (Moghaddam 267 
et al., 2011). To investigate if such increased temperatures are required for liposome production using 268 
microfluidics, we prepared various DSPC liposome formulations with increasing cholesterol 269 
concentrations (from 10:1 to 10:5 wt/wt ratio equivalent to 5 to 50 mol%; initial lipid concentration 270 
of 4 mg/mL) at a range of process temperatures (controlled within the NanoassemblrTM) from room 271 
temperature to 60oC (Figure 1C and 1D). The results demonstrate that all liposome formulations could 272 
be prepared at room temperature with no impact on the liposome size, irrespective of the transition 273 
temperature of the cholesterol concentration or the main PC lipid (in this case 55oC). The key factor 274 
controlling the liposomes size across these formulations is the cholesterol content (Figure 1C); 275 
increasing cholesterol content reduces liposome size from approximately 150 nm (10:1 wt/wt ratio) 276 
down to around 50 nm when equimolar DSPC:Cholesterol is employed as the formulation. Again whilst 277 
the formulation composition was shown to impact on the liposome size, there was no impact on the 278 
homogenous nature of the liposome suspensions with all formulations showing PDI values below 0.2 279 
(Figure 1D). These results demonstrate liposome formulations with a range of transition temperatures 280 
can be prepared using microfluidics without employing heating thereby circumventing any concerns 281 
of heat-induced degradation of the drug/lipids being incorporated.  282 
The ability to manufacture liposomes from high transition temperature lipids without the need to 283 
work above the phase transition temperature of the lipids is a strong attribute of this manufacturing 284 
method as it circumvents risks of thermo-instability issues. The ability to manufacture liposomes at 285 
room temperature, irrespective of the transition temperature of the lipids incorporated, may result 286 
from the rapid ‘bottom up process’ of microfluidics. In this process, the liposomes are formed from 287 
individual monomers, thus the phase transition of the lipids in the bilayer does not influence the 288 
process compared to other methods where lipids need to be hydrated into liposomes and bilayers 289 
need to break-down and reform. Whilst the presence of cholesterol in formulations can help with this 290 
process by reducing transition temperature of the bilayer, this is generally only at molar 291 
concentrations of 50 % (Moghaddam et al., 2011). Cholesterol is commonly incorporated into 292 
liposomal formulations due to its well documented ability to enhance the stability of the vesicles and 293 
reduce drug leakage and membrane permeability, as first reported by Gregoriadis and Davis, (1979). 294 
Cholesterol enhances the stability of liposome bilayers by increasing the packing densities of the 295 
phospholipids (Semple et al., 1996) due to the cholesterol packing within molecular cavities formed 296 
by the lipid molecules as they arrange in the bilayer (Devaraj et al., 2002). This space-filling action of 297 
cholesterol thereby results in a more compact bilayer (Epand et al., 2003). This increased packaging 298 
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of the lipids and compact bilayer maybe the driver behind the smaller liposome sizes produced at 299 
higher cholesterol concentrations (Figure 1C). As mentioned, the addition of 50% mol/mol cholesterol 300 
has been shown by differential scanning calorimetry to abolish the gel-to-liquid phase transition 301 
temperature of DSPC liposomes (Moghaddam et al., 2011). However, at all concentrations tested (5 302 
to 50% mol/mol; Figure 1C and D), liposomes can be manufactured without the need to work at 303 
temperatures above the transition temperature of the main (DSPC) lipid. This confirms that the 304 
bottom-up building of the liposomes from monomers during the microfluidic process negates the 305 
need for heating during the production of liposomes irrespective of their lipid transition temperature. 306 
The initial solubility of the lipids in solvents may still be a consideration for some formulations and can 307 
be improved via adopting increased temperatures. However, across all the formulations and 308 
concentrations tested within these studies no heating was required in the processes.   309 
Given that our results demonstrate both the initial lipid concentration and lipid choice impact on the 310 
size of liposomes formed, we further investigated the impact of the flow rate ratio at which we mix 311 
our solvent and aqueous phases during liposome production. Figure 2A to C demonstrate the effect 312 
of initial lipid concentration and flow rate ratio on the size and PDI of liposomes formed from 313 
DSPC:Chol (10:5 wt/wt). As can be seen, a flow rate ratio of 1:1 can be used to form larger liposomes 314 
(100 to 200 nm depending on the initial lipid concentration selected; Figure 2A) compared to the 3:1 315 
and 5:1 mixing flow rate (Figure 2B and C respectively). These larger liposomes formed at the 1:1 flow 316 
rate are not linked to an increasingly heterogeneous liposomes population as in all cases the PDI 317 
remains low (≤0.2; Figure 2A). By increasing the flow rate ratio to 3:1, we can produce liposomes in a 318 
smaller size range (50 to 60 nm) again with a low PDI (≤0.2) (Figure 2B). When working at 5:1 flow 319 
ratios, we tend to see more heterogeneous populations with slightly higher PDI values unless higher 320 
initial lipid concentrations are used (above 2 mg/mL; Figure 2C). Given these results, we also 321 
considered the normal operating range for anionic liposomes (DSPC:Chol:PS; 10:5:4 wt/wt) (Figure 322 
2D). From these results we see that at a 3:1 flow ratio, liposomes of 50 to 60 nm are produced across 323 
the range of concentrations tested with initial lipid concentrations of 2 mg/mL and above giving us 324 
PDI values of <0.2 (Figure 2D).  We further considered the rate at which we could produce our 325 
liposomes by considering flow rates of 5 to 20 mL/min. Figure 2E and 2F confirms we can produce 326 
liposomes within the same size range and low PDI at a range of flow rates with no significant difference 327 
between the batches produced. These results demonstrate we can apply similar operating parameters 328 
for both neutral and anionic formulations and achieve highly reproducible and homogenous liposome 329 
formulations. 330 
Previous studies by Kastner et al using liposomal formulation DOPE:DOTAP and PC:Chol on a staggered 331 
herringbone micromixer chip show a reduction in average liposome size as the flow rate ratio was 332 
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increased from 1:1 to 5:1. The average liposome size of the formulations at a flow rate ratio of 1:1 333 
resulted in sizes above 200 nm, while a flow rate ratio of 5:1 generated sizes around 50 nm (Kastner 334 
et al., 2014) (Kastner et al., 2015). Similar results were obtained by Jahn et al where the authors 335 
showed that as the flow rate ratio was increased, the resulting particle size decreased. This was 336 
attributed to the difference in the alcohol content of the flow rate ratios, as the flow rate ratio 337 
decreases the amount of alcohol injected into the stream increases. When the lipids in alcohol first 338 
come in contact with the aqueous stream, liposomes will self-assemble and form at the interface. As 339 
the streams then continue to mix, the initially formed liposomes take alcohol up and reach the critical 340 
alcohol concentration resulting in some partial disassembly, the continuing mixing will then decrease 341 
the alcohol concentration in the liposomes again, resulting in re-assembly. When the flow rate ratio is 342 
increased, the overall alcohol concentration is reduced, thus the amount of liposomes exposed to 343 
fluctuating increases and decreases of alcohol is reduced thus limiting the assembly / re-assembly 344 
cycle (Jahn et al., 2010) (Jahn et al., 2007). Similar findings were also reported by Zizzari et al for the 345 
liposomal formulation HSPC:Chol:mPEG-2000-DSPE produced over a range of flow rate ratios. Again, 346 
Zizzari et al note that at higher flow rate ratios, a smaller solvent stream results and as the lipid discs 347 
form at the liquid interface they begin to bend, eventually forming a vesicular particle as a result of 348 
surface area of the hydrophobic chains in the presence of decreasing solvent concentration. The 349 
length of time these lipid discs are allowed to grow will directly impact upon the final vesicle size, with 350 
shorter times leading to smaller liposomes. Thus at lower flow rate ratios (e.g. 1:1), the higher the 351 
concentration of solvent and thus the longer the time the lipid discs have to expand (Zizzari et al., 352 
2017). Whilst the flow rate ratio has been shown to impact upon liposome size and thus should be 353 
tested to identify the normal operating range for a given formulation, the total flow rate (TFR mL/min) 354 
did not impact on the liposome size and with the formulations tested a flow rate of 5 to 20 mL/min is 355 
a proven acceptable range to work within. This is in line with previous work reported by Joshi et al 356 
where again the flow ratio was shown to impact on particle size of PC:Chol liposomes, but flow rate 357 
had no impact across all speeds tested (Joshi et al., 2016). Therefore, we have established that by 358 
choosing the appropriate initial lipid concentration in the tested range of flow rates, we can control 359 
liposome size and maintain low (<0.2) PDI values through selection of flow ratios in combination with 360 
the initial lipid concentration. For all formulations, a heating step can be eliminated circumventing any 361 
potential thermal protein denaturation occurring. 362 
3.2 Purification and concentration of liposomal systems.  363 
To ensure removal of residual solvent and non-incorporated protein, liposomes were purified via 364 
tangential flow filtration (TFF). To validate the purification process and confirm solvent removal, 365 
residual solvent levels were quantified via headspace gas chromatography (Figure 3A). Results show 366 
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that after 12 wash cycles solvent levels were below ICH guidelines of less than 3000 parts per million 367 
(or less than 0.3% of residual solvent remaining) (International conference in Harmonisation, 2016 368 
(ICH)). Similarly, this wash cycle was able to remove all non-incorporated protein (Figure 3B). This was 369 
confirmed by mixing pre-prepared ‘empty’ liposomes and with various protein concentrations. Given 370 
the protein was not entrapped, 100% removal confirms all free protein can be removed. Figure 3C, 371 
confirms the TFF process has no detrimental effect on the liposome attributes with the particle size, 372 
PDI and morphology remaining unchanged, and liposome recovery was high (95-100%; results not 373 
shown).  374 
Using TFF, we were also able to concentrate both the neutral (Figure 4A and B) and anionic liposome 375 
formulations (Figure 4C and D) up to 4 fold, without any determent to their vesicle attributes with four 376 
cycles being sufficient to double the concentration of liposomes. The recovery of the liposomes was 377 
again 95-100% (results not shown) similar to studies where a lab-on-chip TFF purification system was 378 
adopted (Dimov et al., 2017).  The ability to purify liposome formulations in a scalable format is an 379 
important feature of any manufacturing process. Furthermore, the lipid solubility of some lipids within 380 
suitable solvents can be limited and thus TFF can allow the concentration of liposome formulations to 381 
required doses. These studies demonstrate the ability to purify and/or concentrate liposome 382 
formulations in scalable format.  383 
3.3 Scale-independent manufacturing of liposomes entrapping proteins. 384 
Now that we have identified the normal operating range for the microfluidic production and 385 
appropriate purification protocols for a range liposome formulations, we can next consider protein 386 
loading of these liposomes. First, we compared protein loading of liposomes composed of DSPC:Chol 387 
(10:5 wt/wt) prepared by microfluidics, sonication and extrusion. Liposomes produced by 388 
microfluidics gives high protein loading (25 – 35%; 250 µg/mL initial protein concentration), whilst 389 
both sonication and extrusion gave low (< 5%) protein loading (Figure 5A). Microfluidics also produced 390 
small vesicles (60 to 70 nm; PDI 0.2) similar in size to ‘empty’ liposomes and notably smaller and more 391 
homogeneous than vesicles formed from sonication or extrusion (Figure 5A). The similarity in size 392 
between loaded and unloaded liposomes suggests that in the initial process development, empty 393 
liposomes can be used, reducing the amount (and cost) of active pharmaceutical ingredient used.  394 
The effect of extrusion on protein loaded MLVs has previously been shown to reduce the 395 
concentration of protein entrapped within the vesicles following extrusion cycles. Large particles that 396 
cannot flow through are blocked at the membrane pores and the pressure from the extrusion process 397 
ruptures the liposomes (Patty and Frisken, 2003). This rupturing coincides with a major decrease in 398 
the encapsulation efficiency of the protein after the first extrusion cycle and the retention of the 399 
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protein upon the filter (Colletier et al., 2002). This presents protein entrapment issues if progressively 400 
smaller and smaller membrane filters are used during the extrusion process to downsize MLVs to size 401 
ranges below 100 nm (which are easily achieved via microfluidics). Similarly, probe sonication of 402 
liposome formulations for size reduction leads to poor encapsulation efficiencies, generally below 10 403 
% for aqueous soluble macromolecules (Lapinski et al., 2007). Although sonication is widely used to 404 
break down MLVs by acoustic energy (Mendez and Banerjee, 2017), there is little control of the end 405 
product with batch to batch variation. A lack of temperature control can also present challenges for 406 
protein encapsulation, and depending on the system, the need to remove contamination post 407 
sonication is an added step to production (Philippot and Schuber, 2017). In comparison, the rapid 408 
production processes, coupled with higher encapsulation efficiencies of protein, demonstrates that 409 
microfluidics is an effective method for one step, scalable production of protein loaded liposomes.  410 
When produced via microfluidics, the choice of lipid used within the liposome formulation has no 411 
significant impact on protein loading with liposomes composed of PC, DMPC, DPPC and DSPC all 412 
showing similarly high (30-40%) protein loading (Figure 5B). These formulations were prepared at 413 
room temperature and Figure 5C shows that the ovalbumin (OVA) contained in liposomes and the 414 
untreated OVA have a similar CD spectra. In addition, the CD spectrum, containing information on the 415 
OVA structure, with nine alpha helical structures and two beta sheets (Stein et al., 1990), is in keeping 416 
with literature (Paolinelli et al., 1997). Therefore, it is concluded from the CD measurements that the 417 
entrapped protein retained its structural conformation during liposome production. 418 
We again investigated the influence of lipid concentration on these systems, this time in relation to 419 
protein encapsulation. Varying amounts of PC, DMPC, DPPC and DSPC liposomes (from 0.5 to 10 420 
mg/mL initial lipid concentration) were used and the encapsulation efficiency of OVA (250 µg/mL) 421 
tested. This was plotted on a double logarithmic plot of the encapsulation versus lipid concentration 422 
as previously done by Colletier et al. (Colletier et al., 2002) (Figure 5D). The authors suggest to do this 423 
as the total liposome surface area is proportional to the lipid concentration, yet the encapsulated 424 
inner volume is proportional to the lipid concentration to the power 3/2. Thus the double log plot 425 
allows the discrimination between the relevant parameters (Colletier et al., 2002). With all 4 liposome 426 
formulations, the data shows a relatively good linear correlation (R2 >0.9). It has been proposed that 427 
if the gradient is close to 1 then encapsulation is proportional to the number of lipids and the surface 428 
area, and if the slope is close to 1.5 this suggest that encapsulation is related to internal volume. Whilst 429 
the plot of DMPC:Chol can be seen to have a gradient close to 1, PC, DPPC and DSPC are notable lower 430 
than 1 and all 4 are far from 1.5. This suggests that the high incorporation of protein within liposomes 431 
using microfluidics is a factor of the manufacturing process and less influenced by the number of lipids 432 
or by the internal volume.  433 
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We further studied the protein loading efficiency of both neutral (DSPC:Chol; 10:5 wt/wt) and anionic 434 
(DSPC:Chol:PS; 10:5:4 wt/wt) liposomes at a fixed lipid concentration and increasing protein 435 
concentrations. Figure 6A shows that up to an initial protein concentration of 2 mg/mL protein 436 
encapsulation efficiency remains high at approximately 30 %, which is equivalent to approximately 437 
400 µg/mL prior to any concentration steps. Over this protein concentration range, the liposome size 438 
and PDI remained stable at around 60 – 80 nm and PDI of ~0.2 (Figure 6B), with a near neutral zeta 439 
potential (Figure 6C). Increasing the protein concentration further, to 10 mg/mL, caused a drop in 440 
encapsulation efficiency (15%) but an increase in the total amount of OVA loaded. However, it also 441 
resulted in aggregation and large particle sizes (above 700 nm; results not shown). Anionic liposomes 442 
(Figure 6D – F) also gave good protein loading over the same range (0.1 to 2 mg/mL initial protein 443 
concentrations) with entrapment efficiencies of ~ 20 % (Figure 6D) and the protein loading within the 444 
liposomes does not influence their particle size, PDI nor zeta potential over this range (Figure 6E and 445 
F).  446 
The decrease in entrapment efficiency with the anionic liposomal formulation compared to the 447 
neutral formulation is not un-common. Colletier et al also investigated the effect of charge on the 448 
entrapment efficiencies of acetylcholinesterase using a neutral lipid POPC and an anionic lipid POPS. 449 
Using multiple freeze-thaw cycles, the anionic formulation achieved an encapsulation efficiency 450 
around 20% while the neutral POPC formulation achieved around 40% acetylcholinesterase 451 
encapsulation indicating the electrostatic interactions between proteins peripheral charge and the 452 
polar head group of the phospholipids has a substantial control over the ability of the entrapment 453 
process within the vesicles (Colletier et al., 2002).  454 
The effect of flow ratio and flow rate was also considered for both these liposome formulations (Figure 455 
7). Only flow rates of 3:1 and 5:1 were considered as a flow ratio of 1:1 was shown to result in 456 
aggregation which may be a result of protein aggregation at high (50%) solvent concentrations (results 457 
not shown). Increasing the flow rate from 3:1 to 5:1 was shown to reduce protein loading by 458 
approximately 10% and increasing the variability in the particle size of the DSPC:Chol liposomes (Figure 459 
7A and B respectively). Working at flow rate of 10 mL/min or above also gave reproducible protein 460 
loading (20 – 25%; 700 µg/mL initial ovalbumin concentration), particle size (55 – 65 nm) and PDI (~0.2) 461 
(Figure 7C and D). This is again comparable to our data with empty liposomes (Figure 2). Similar results 462 
were shown with the anionic liposomes (DSPC:Chol:PS); increasing the flow rate ratio from 3:1 to 5:1, 463 
significantly (p<0.05) reduced protein loading from 20% to 9% (Figure 7E) without influencing 464 
liposome size (100 – 110 nm; Figure 7F). Again working at a flow rates of 10 mL/min or more giving 465 
protein loading of 20 – 25 % with no significant impact on protein loading (Figure 7G) nor particle size 466 
(which remained around 100 to 120 nm; Figure 7H). With both formulations, working a low flow rate 467 
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of 5 mL/min did reduce protein loading despite particle size remaining the same. This again suggests 468 
that protein entrapment efficiency is controlled more by the manufacturing than the lipid/protein 469 
concentrations and thus can be easily scaled within identified normal operating ranges. 470 
In order to determine the effect of flow rate ratio on the protein encapsulation efficiency, the final 471 
lipid and protein concentrations described in figure 7 were matched by adjusting the initial 472 
concentrations. Despite controlling for these variables, a significantly lower protein entrapment 473 
efficiency is observed when the flow rate ratio is increased from 3:1 to 5:1. The difference in 474 
encapsulation efficiency between the flow rate ratios could be due a shift in position of the liquid-475 
liquid interface between the two different flow rate ratios during liposome production in the chip 476 
(Oellers et al., 2017). At a 1:1 FRR the liquid-liquid interface (the mixing of the solvent and aqueous 477 
phase) occurs at the centre of the chip, with this position changing in accordance to the FRR selected. 478 
Carugo et al also note that changes in the flow rate ratio have a direct impact upon the fluid stream, 479 
thus altering the properties of the fluidic environment within the chip which could impact upon the 480 
interactions between the lipid phase and aqueous protein during liposomal formation (Carugo et al., 481 
2016).  482 
Given the various parameters for optimal loading have been established, these parameters were then 483 
tested with two additional proteins (Table 4) and in a 10 times scaled process (Figure 8). Table 4 484 
demonstrates that both a smaller protein (insulin) and larger protein (bovine serum albumin) can also 485 
be effectively entrapped (25 to 37 %) within DSPC:Chol liposomes prepared using the optimised 486 
parameters, with liposomes in a similar size range (55 - 70 nm) being produced. Furthermore, to 487 
demonstrate the scalability of the process, two batches of liposomes (DSPC:Chol) were prepared by 488 
either the small-laboratory scale NanoAssemblr® Benchtop (1 -15 mL batch size) and the larger Blaze™ 489 
(10 mL to 1 L batch size) entrapping OVA. Across both platforms, liposomes were manufactured with 490 
reproducible results in terms of protein loading and particle attributes (Figure 8), demonstrating the 491 
easy scale-up of the process developed.   492 
3.4 Release characteristics of liposomes entrapping protein 493 
The ability of liposome formulations to retain, delivery and release protein is important. Release 494 
profiles of protein in-vitro can be used to determine behaviour in vivo. The release rate of protein 495 
from liposomes is highly dependent on factors such as liposome composition and the nature of the 496 
protein entrapped (Panagi et al., 1998). The effect of liposome composition was investigated using 497 
four neutral liposomes containing cholesterol. Lipids with varying carbon chain lengths were tested to 498 
investigate the effect of tail length on release. Figure 9A shows all four neutral formulations (PC:Chol, 499 
DMPC:Chol, DPPC:Chol and DSPC:Chol) are capable of protein release. The general trend observed 500 
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confirms previous research whereby, the longer hydrocarbon tailed lipids used the slower the release 501 
(e.g. Panagi et al., 1998). OVA is fully released from PC:Chol liposomes within 72 hours, meanwhile 502 
both DPPC:Chol and DSPC:Chol do not fully release OVA by 120 hours; there is 9% OVA remaining for 503 
DPPC:Chol and 47% OVA remaining for the DSPC:Chol liposomes after 5 days. The findings are in 504 
keeping with previous studies showing liposomes formulated from longer chain lipids have slower 505 
release rates due to their increased bilayer rigidity. Longer chain lipids, such as DSPC, have more 506 
opportunity to create Van der Waals forces between the longer hydrocarbon tails and improved 507 
membrane packing compared to liposomes composed of shorter chain phosphatidylcholines 508 
(Mohammed et al., 2004; Panagi et al., 1998). Moreover, the release profiles for PC:Chol, DMPC:Chol 509 
and DPPC:Chol liposomes prepared by microfluidics match previous studies whereby a burst release 510 
is observed within the first 12 hours, after which  a slower rate of release is observed (Monteiro et al., 511 
2014; Murao et al., 2002; Panagi et al., 1998).  512 
In addition, given the ability to manipulate the flow rate ratio to change liposomal formulation 513 
characteristics, the effect of this ratio on protein release from liposomes was investigated. Two 514 
formulations (DMPC:Chol and DSPC:Chol) were used to investigate any possible changes in release 515 
caused by the selected manufacturing process. The encapsulation efficiency for DMPC:Chol liposome 516 
formulations produced at a 3:1 FRR is 37 ± 0.2 % and 29 ± 0.6 % for DMPC:Chol liposomes produced 517 
at a 5:1 FRR. Figure 9B shows the 5:1 FRR releases the protein OVA at a faster rate in comparison to 518 
the DMPC:Chol liposomes produced at a 3:1 FRR with a similarity factor (f2) of 24.6 being calculated 519 
(it is generally accepted that an f2 of 50-100 suggests similar release profiles). The same pattern is also 520 
observed for OVA loaded DSPC:Chol liposomes produced at a 3:1 and 5:1 FRR (Figure 8C), with the 521 
DSPC:Chol liposomes produced at a 5:1 showing a faster release rate (f2 of 48.3) than DSPC:Chol 522 
liposomes produced at 3:1 despite the amount of protein loaded within these formulations being 523 
matched (0.1875 ug/mL final OVA concentration). Similar to the differences noted in encapsulation 524 
efficiency of the liposomes produced by FRRs, a range of factors may be responsible for the effect of 525 
flow rate ratio on release rate.  As previously mentioned, when the flow rate ratio is increased, the 526 
alcohol concentration is reduced, which reduces the opportunity for liposomes to re-assemble during 527 
their production (Jahn et al., 2010) (Jahn et al., 2007). Also at lower alcohol concentrations, there is 528 
less time for lipid discs to expand and form liposomes (Zizzari et al., 2017); different flow rate ratios 529 
result in a shift in position of the liquid-liquid interface (Oellers et al., 2017). Each or all of these factor 530 
may impact on the assembly of the liposomal bilayers which in turn will impact on release profiles. A 531 
shift in the position of the liquid-liquid interface and/or differences in the ethanol concentrations 532 
could result in subtle changes in the cholesterol tilt within the liposome bilayers. Indeed, the position 533 
of cholesterol is highly variable with concentration and production method used. Research by 534 
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Khelashvili and Harries (Khelashvili and Harries, 2013; Khelashvili et al., 2010), has shown that 535 
DMPC:Chol liposomes with a cholesterol concentration of more than 30%, preferred an upright 536 
position so it is more aligned to the phospholipid bilayer (Khelashvili and Harries, 2013). Therefore, in 537 
the bottom up process, the solvent concentration at the point of formation may impact of the 538 
orientation/alignment of cholesterol thus impacting on protein release. This manufacturing 539 
parameter controlled change in release profile, further demonstrating microfluidic is a versatile 540 
system. It can be fine-tuned to modify liposome attributes and the flow rate ratio is a key quality 541 
attribute which influences particle size, protein loading and protein release.  542 
3.5 Continuous manufacture with at-line size analysis 543 
High-throughput production of liposomes using microfluidics requires an ability to monitor liposome 544 
attributes during manufacturing. In particular, liposome size is a key product attribute given the 545 
impact this can have on drug loading, drug release and biodistribution. Therefore, the ability to 546 
monitor liposome size rapidly during production is a key element of a manufacturing process. To 547 
achieve this, we incorporated at-line (in real time) particle size monitoring using the Malvern Zetasizer 548 
AT (Malvern Instruments, Malvern, UK) both for in-process monitoring and for product validation 549 
(Figure 10). The sensitivity of this instrument was compared to the off-line characterising equipment 550 
(the Zetasizer Nano ZS) and two monitoring points in the production of DSPC:Chol liposomes were 551 
tested: in-process (directly after production) and the final purified product. The results in figure 10 552 
confirm that the liposome size can be effectively monitored in real time (at-line) at both points in the 553 
process. After production, the liposome sizes recorded were 49 ± 0.4 nm when measured at-line 554 
compared with 50 ± 0.3 when measured off-line. Similarly, after purification, the final liposome 555 
product particle size was 52 ± 0.4 nm when measured at-line compared with 52 ± 0.7 nm when 556 
measured off-line.  There was also no significant difference in the PDI measured by both instruments 557 
after microfluidics (~0.06 PDI) and post purification (~0.15 PDI), thus indicating a rapid at-line particle 558 
size analysis can be incorporated within this continuous and scalable-independent process for 559 
monitoring liposomal formulation quality in real-time.  560 
4. Conclusions 561 
We have successfully shown for the first time, a simple and scale-independent method to 562 
manufacture, purify and monitor the production of liposomes encapsulating proteins. This process 563 
gives high protein loading and can be undertaken at room temperature thereby circumventing any 564 
potential risk to the protein structure. Key process parameters identified are the lipid concentration, 565 
the liposome composition, the protein concentration and the flow rate ratio. This microfluidic 566 
manufacturing process ensures a quick and efficient process for the translation of novel liposome 567 
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formulations from the bench to production and de-risks the adoption of liposomes for wide-scale 568 
applications. 569 
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Tables 695 
Table 1. Examples of traditional methods used to entrap proteins within liposomes and their relative 696 
entrapment efficiencies. The efficiency of neutral and anionic liposomes to encapsulate protein was 697 
investigated relative to the manufacturing methods.   698 
Protein loaded Liposome formulation Production 
technique 
Protein loading Reference 
Bovine serum albumin soyabean PC/DSPC, 
cholesterol, 
phosphatidylglycerol  
Thin film lipid 
hydration. 
0.1 mg/mL (Ramaldes et al., 
1996) 
Bovine serum albumin PC:Chol  
 
Dehydration-
rehydration 
method. 
28% (Chan et al., 
2004) 
Bovine Serum Albumin  PC:Chol:Tween:Vitamin E  Thin film lipid 
hydration. 
34 ± 9% (Liu et al., 2015) 
 
Bovine Serum Albumin  Soybean PC:Chol  Thin film lipid 
hydration. 
22-32%.  (Vila-Caballer et 
al., 2016) 
Ovalbumin PC:Chol 
 
Thin film lipid 
hydration. 
10% (Habjanec et al., 
2006) 
Ovalbumin  Phospholipid S, Chol  
(very high lipid 
concentration, 200 mg) 
Thin film lipid 
hydration. 
48% ± 9% (Li et al., 2011) 
Amyloglucosidase, 
Albumin 
PC:Chol:Dicetylphosphate Lipid film 
hydration 
4 - 6.5%, 
6.8 - 10.6% 
(Gregoriadis et 
al., 1971) 
Superoxide dismutase DPPC:Chol  
DSPC:Chol 
 
Unilamellar 
vesicles mixed 
with freeze- 
thaw cycling 
50%  (Xu et al., 2012) 
Acetylcholinesterase Egg PC Thin film lipid 
hydration. 
35% (Colletier et al., 
2002) 
Insulin Hydrogenated PC:Chol  Thin film lipid 
hydration.  
28% (4°C)  
30% (25°C) and 
50% (40°C) 
(Huang and 
Wang, 2006) 
 699 
Table 2. Lipid recovery in liposomes produced by microfluidics. Four liposomal formulations (PC:Chol, 700 
DMPC:Chol, DPPC:Chol and DSPC:Chol each at 2:1 wt/wt) were manufactured using microfluidics at a 701 
flow rate ratio of 3:1, 15 mL/min TFR and purified using dialysis. Lipid recovery was calculated using 702 
HPLC-ELSD. Results represent mean ± SD, n=3 independent batches.  703 
 Lipid recovery (% of initial amount) 
Formulation PC:Chol DMPC:Chol DPPC:Chol DSPC:Chol 
Lipid PC Chol DMPC Chol DPPC Chol DSPC Chol 
Recovery 94 ± 5.0 95 ± 2.3 95 ± 1.6 96 ± 1.0 96 ± 1.2 97 ± 2.7 98 ± 5.7 97 ± 3.8 
 704 
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Table 3. Comparison of particle size of liposomes formulated from phospholipids of different phase 705 
transition temperatures manufactured via microfluidics. Two liposome formulations (DSPC:Chol 706 
(10:5 wt/wt) and DOPC:Chol (10:5 wt/wt), initial lipid concentration of 1 mg/mL) were manufactured 707 
using microfluidics at a flow rate ratio of 3:1, 15 mL/min TFR and purified using dialysis. Results 708 
represent mean ± SD, n=3 independent batches.  709 
 Carbon chain 
length 
Tm (°C) Saturation Particle size 
(nm) 
PDI 
DOPC 18 carbons -17 18:1c9 84.9 ± 4.3 0.13 ± 0.04 
DSPC 18 carbons 55 18:0 41.5 ± 0.2 0.03 ± 0.01 
Table 4. Comparison of entrapment of different proteins. In total three different proteins (Insulin, 710 
Bovine Serum Albumin (BSA) and OVA) were incorporated into DSPC:Chol liposomes ( 2:1 wt/wt) 711 
manufactured using microfluidics at a flow rate ratio of 3:1, 15 mL/min TFR and purified via TFF. An 712 
initial protein concentration of 250 µg/mL was employed. Results represent mean ± SD, n=3 713 
independent batches.  714 
  715 
  716 
Protein Protein Loading 
 (% of initial amount added) 
Liposome Size  
(d.nm) 
Liposome PDI 
Insulin (5.7 KDa) 36.8 ± 2.7 57 ± 2.9 0.087 ± 0.062 
OVA (42.7 KDa) 34.2 ± 4.9 53 ± 2.5 0.219 ±0.011 
BSA (65.5 KDa) 25.2 ± 2.8 65 ± 2.8 0.144 ± 0.021 
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Figures. 717 
 718 
Figure 1: The effect of liposomal formulation on physicochemical characteristics of liposomes 719 
produced by micofluidics. Four liposome formulations (PC:Chol, DMPC:Chol, DPPC:Chol, and 720 
DSPC:Chol) with increasing hydrocarbon tail length were manufactured using microfluidics at a 3:1 721 
FRR, 15 mL/min TFR and purified using dialysis. The effect of PC lipid chain length on A) liposomes z-722 
average size (d.nm) and B) PDI. DSPC:Chol liposomes were selected and the effect of cholesterol 723 
content and heating block temperature were investigated in regards to C) z-average particle size and 724 
D) PDI. Results represent mean ± SD, n=3 independent batches. 725 
  726 
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727 
Figure 2: The effect of microfluidic parameters on neutral and anionic liposome attributes. The effect 728 
of the initial lipid concentration on average liposome size (d.nm; represented by bars) and PDI 729 
(represented by discrete points) for liposomal formulation DSPC:Chol (10:5 wt/wt) (10 mL/min TFR) 730 
at a flow rate ratio of A) 1:1, B) 3:1, and C) 5:1. D) The effect of increasing initial lipid concentration on 731 
z-average particle size (d.nm) for DSPC:Chol:PS (10:5:4 wt/wt) (3:1 FRR, 10 mL/min TFR). E) 732 
Investigating the effect total flow rate (mL/min) on z-average particle size (d.nm) and PDI for liposomal 733 
formulation DSPC:Chol (4 mg/mL initial lipid, 3:1 FRR). F) The effect of total flow rate (mL/min) for 734 
anionic formulation DSPC:Chol:PS (4 mg/mL initial lipid, 3:1 FRR). Results represent mean ± SD, n =3 735 
of independent batches.  736 
  737 
27 
 
738 
Figure 3: Purification of liposomes using tangential flow filtration (TFF). Liposomes (DPPC:Chol; FRR 739 
3:1, 15 mL/min TFR) were prepared and characterised as follows: A) Residual solvent (methanol) 740 
remaining in liposomes after consecutive wash cycles, B) removal of non-incorporated protein via TFF, 741 
C) liposome attributes before and after purification via TFF and cryo-EM images of liposomes before 742 
and after TFF purification. Results represent mean ± SD, n =3 of independent batches. 743 
  744 
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745 
Figure 4: Concentration of liposomal formulations using tangential flow filtration. DSPC:Chol (10:5 746 
wt/wt) and DSPC:Chol:PS (10:5:4 wt/wt) were prepared  at 4 mg/mL initial lipid concentration, 3:1 747 
FRR, 15 mL/min TFR following microfluidics, followed by 1,2 and 4 fold concentration steps. Particle 748 
Size (Z-Avg; represented by bars) and PDI (represented by discrete points) for A) DSPC:Chol and B) 749 
DSPC:Chol:PS both prepared C) and D) are intensity plots for the same conditions. Results represent 750 
mean ± SD, n =3 of independent batches. 751 
  752 
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753 
Figure 5. Manufacture of protein loaded liposomes using microfluidics. A) Ovalbumin loading and 754 
physicochemical comparison between microfluidics and lipid-film hydration followed by extrusion or 755 
sonication. DSPC:Chol (10:5 wt/wt) liposomes were made with 1 mg/mL final total lipid and 0.18 756 
mg/mL ovalbumin. The encapsulation efficiency, size and PDI of the liposomes. B) Microfluidics was 757 
further tested with respect to changes in lipid hydrocarbon tail length and concentration. Protein 758 
encapsulation, size and PDI for PC:Chol, DMPC:Chol, DPPC:Chol and DSPC:Chol (4 mg/ mL initial lipid 759 
and 0.25 mg/ mL Ovalbumin) made using microfluidics (3:1 FRR and 15 mL/ min TFR). C) The structural 760 
integrity of ovalbumin loaded into the liposomes measured by circular dichroism. DSPC:Chol (10:5 761 
wt/wt) liposomes were prepared with OVA (8 mg/mL initial total lipid and OVA, 3:1 FRR, 15 mL/min 762 
TFR) and purified via TFF. Spectra was measured across 180 – 260 nm D) Log-log plot of lipid 763 
concentrations (0.5- 10 mg/ mL) against encapsulation efficiency (0.25 mg/ mL ovalbumin). Results 764 
represent mean ± SD, n=3 independent batches. 765 
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767 
Figure 6: The effect of protein concentration in aqueous phase on entrapment efficiency and liposomal 768 
physicochemical characteristics for a neutral liposomal formulation (DSPC:Chol; 10:5 wt/wt) (A to C) 769 
and anionic formulation (DSPC:Chol:PS; 10:5:4 wt/wt) (D to F) using initial total lipid concentration of 770 
4 mg/mL, 3:1 flow rate ratio and 15 mL/min TFR. A) Entrapment efficiency and protein loading across 771 
initial ovalbumin concentrations for neutral liposomal formulation. B) Average particle size and PDI, 772 
and C) Zeta potential for the same formulation. D) Entrapment efficiency and protein loading across 773 
initial ovalbumin concentrations for anionic liposomal formulation, E) Average particle size and PDI 774 
and, F) Zeta potential for the same formulation. In B) and E) particle size is shown by bars and PDI is 775 
shown by discrete points. Results represent mean ± SD, n=3 of independent batches.  776 
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778 
Figure 7: Microfluidic manufacture of neutral and anionic liposomes encapsulating protein. Both 779 
neutral (DSPC:Chol; 10:5 wt/wt) (A to D) and anionic (DSPC:Chol:PS; 10:5:4 wt/wt) (E to H) were tested: 780 
A) Entrapment efficiencies for flow rate ratios 3:1 and 5:1 for DSPC:Chol (final lipid and OVA 781 
concentrations matched at 1 mg/mL and 0.525 mg/mL respectively). B) Average particle size and PDI 782 
for the same formulation C) Entrapment efficiencies with varying on total flow rate (mL/min) (3:1 flow 783 
rate ratio, 4 mg/mL and 0.7 mg/mL initial total lipid and OVA respectively) and D) the resulting particle 784 
size (d.nm) and PDI with varying total flow rate. E) Effect of flow rate ratio on entrapment efficiency 785 
for DSPC:Chol:PS (final lipid and OVA concentrations matched at 1 mg/mL and 0.525 mg/mL 786 
respectively). F) Entrapment efficiencies with varying on total flow rate (mL/min) (3:1 flow rate ratio, 787 
4 mg/mL and 0.7 mg/mL initial total lipid and OVA respectively) and H) the resulting particle size (d.nm) 788 
and PDI with varying total flow rate. Where appropriate liposome size is shown by bars and PDI is 789 
shown by discrete points. Results represent mean ± SD, n=3 of independent batches. 790 
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792 
Figure 8: Proof-of-concept scale-out studies. DSPC:Chol liposomes were prepared at a FFR 3:1, TFR 15 793 
mL/min, and a concentration of 10 mg/mL on both the NanoAssemblr (total volume 2 mL) and Blaze 794 
(total volume 20 mL). A) The protein loading, size and polydispersity index (PDI) of both batches and 795 
B) an overlay of the intensity plots for both batches.  796 
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798 
Figure 9. Protein release from liposome formulations manufactured by microfluidics. A) The release 799 
of OVA from PC:Chol, DMPC:Chol, DPPC:Chol and DSPC:Chol liposomes produced at a 3:1 ratio (15 800 
mL/mi TFR) over 120 hours. B) Ovalbumin release from DMPC:Chol liposomes produced at a 3:1 and 801 
5:1 FRR  (15 mL/min TFR.) C) Ovalbumin release from DSPC:Chol liposomes produced at a 3:1 and 5:1 802 
FRR  (15 mL/min TFR, matched at a final concentration of 1 mg/mL total lipid, 0.1875 mg/mL OVA) 803 
Liposome suspensions were kept at 37°C with agitation. At set times, the sample was collected the 804 
OVA remaining inside the liposomes quantified. The results represent the mean of three independent 805 
batches ± SD.    806 
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 808 
Figure 10: Liposome at-line particle size monitoring as part of a production train. DSPC:Chol liposomes 809 
were prepared at a FFR 3:1, TFR 15 mL/min, and a concentration of 10 mg/mL. The size and 810 
polydispersity index (PDI) of all formulations were measured (at a ratio of 1:10) off-line using the 811 
Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) or at-line as part of the automated continuous 812 
manufacturing process using the Zetasizer AT (Malvern Instruments, Malvern, UK). To characterise 813 
liposomes in real time, the Zetasizer AT measured liposome size and PDI at a 1:10 dilution (liposomes 814 
to buffer), with adjustments to the automated mixing possible. The buffer (5 mL/min) and liposome 815 
formulation (0.5 mL/min) are taken up by the instrument, and enter into the flow cell where the size 816 
and PDI was measured. A total of 1 mL was required for each size measurement. Liposome 817 
formulations were purified using the KrosFlo Research Iii TFF system.  818 
